The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells.

Princeton University, Department of Molecular Biology, Lewis Thomas Laboratory, Princeton, New Jersey, United States of America.
PLoS Pathogens (Impact Factor: 8.06). 08/2012; 8(8):e1002853. DOI: 10.1371/journal.ppat.1002853
Source: PubMed

ABSTRACT Vectors derived from human adenovirus type 5, which typically lack the E1A and E1B genes, induce robust innate immune responses that limit their therapeutic efficacy. We reported previously that the E1B 55 kDa protein inhibits expression of a set of cellular genes that is highly enriched for those associated with anti-viral defense and immune responses, and includes many interferon-sensitive genes. The sensitivity of replication of E1B 55 kDa null-mutants to exogenous interferon (IFN) was therefore examined in normal human fibroblasts and respiratory epithelial cells. Yields of the mutants were reduced at least 500-fold, compared to only 5-fold, for wild-type (WT) virus replication. To investigate the mechanistic basis of such inhibition, the accumulation of viral early proteins and genomes was compared by immunoblotting and qPCR, respectively, in WT- and mutant-infected cells in the absence or presence of exogenous IFN. Both the concentration of viral genomes detected during the late phase and the numbers of viral replication centers formed were strongly reduced in IFN-treated cells in the absence of the E1B protein, despite production of similar quantities of viral replication proteins. These defects could not be attributed to degradation of entering viral genomes, induction of apoptosis, or failure to reorganize components of PML nuclear bodies. Nor was assembly of the E1B- and E4 Orf6 protein- E3 ubiquitin ligase required to prevent inhibition of viral replication by IFN. However, by using RT-PCR, the E1B 55 kDa protein was demonstrated to be a potent repressor of expression of IFN-inducible genes in IFN-treated cells. We propose that a primary function of the previously described transcriptional repression activity of the E1B 55 kDa protein is to block expression of IFN- inducible genes, and hence to facilitate formation of viral replication centers and genome replication.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although several Ad5 proteins prevent deleterious consequences of activation of p53, it has been reported that viral replication proceeds more efficiently when human tumor cells produce wild-type compared to mutant p53. We have now exploited RNA interference and lentiviral vectors to achieve essentially complete knockdown of p53 in normal human cells: no effects on the kinetics or efficiency of viral gene expression, or production of infectious particles, were observed.
    Journal of Virology 03/2013; · 4.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The virus-associated (VA) RNAs were originally discovered in 1966 as a remarkably abundant class of small RNAs selectively accumulating in adenovirus type 2 (Ad2)-infected cells; hence the term VA RNAs [1]. Subsequent studies dem-onstrated that Ad2 encodes two VA RNA spe-cies; a major species designated VA RNAI, which was the VA RNA originally detected in the Reich et al. study, and a minor species, VA RNAII, expressed by most but not all adenovirus sero-types [2–4]. The Ad2 VA RNAs are between 157 and 163 nucleotides long, noncoding RNAs that can form extensive intramolecular base-paired regions [5]. The exact length of the Ad2 VA RNAs varies slightly due to a small heterogeneity at both the 5VA RNAI) and 3VA RNAI and VA RNAII) ends of the molecules [2]. The VA RNAs are transcribed by RNA polymerase III and accumulate in large amounts late during infection (10 8 copies per cell). Both VA RNAs are made in approximately equal amounts dur-ing the early phase of the virus infection [3]. However, following viral DNA replication, the amount of DNA templates for transcription increases dramatically. Since the VA RNAI promoter is intrinsically stronger than the VA RNAII promoter, and both genes compete for the same RNA polymerase III transcription fac-tors, this results in a preferential increase in VA RNAI accumulation at late stages of infection, leading to a 20–40-times higher accumulation of VA RNAI [3]. In mutant viruses defective in VA RNAI expression, VA RNAII transcription continues to increase late after infection, corrob-orating the idea that transcriptional competition controls the accumulation of the two species [6]. The VA RNA genes are regulated by intra-genic control elements similar to tRNA genes [7,8]. The locations and functions of these ele-ments, known as box A and box B, have been thoroughly mapped by mutational ana lysis [9–11]. For example, in Ad2 VA RNAI, the box A (position +17 to +27) and box B (position +62 to +72) have been shown to be essential for VA RNA transcription (Figure 1) [10]. From muta-tional studies, it has been concluded that box B is most crucial for efficient VA RNAI transcrip-tion, since it was more sensitive to mutations compared with box A. This can be explained by the critical role of the cellular transcription factor TFIIIC binding to box B to support recruitment of RNA polymerase III to the VA RNAI transcription unit [8,12]. Thus, TFIIIC has been considered to be the rate-limiting factor for VA RNA transcription. To circum-vent the restrictive role of TFIIIC, viral early E1A protein can activate TFIIIC and, thereby, stimulate VA RNAI transcription [13,14]. The VA RNAI transcription unit contains two initia-tion sites, the major G start and a minor A start three nucleotides upstream (Figure 1). The VA RNAI(G) start represents approximately 75% of the total VA RNAI population [15]. Many adenovirus gene therapy vectors are based on the Ad5 mutant dl309 [16], which lacks two base pairs, destroying the XbaI site located 23 base pairs upstream of the VA RNAI(A) start site. Such viruses have a defect in transcription ini-tiation and accumulate only the VA RNAI(G) species. However, so far, this failure to express the VA RNAI(A) species has not been associated with any growth defects, at least not in tissue culture experiments [16].
    Future Virology 04/2013; 8:343-356. · 1.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human adenoviruses are the most widely used vectors in gene medicine, with applications ranging from oncolytic therapies to vaccinations, but adenovirus vectors are not without side effects. In addition, natural adenoviruses pose severe risks for immuno-compromised people, yet, infections are usually mild and self-limiting in immuno-competent individuals. Here we describe how adenoviruses are recognized by the host innate defense system during entry and replication in immune and non-immune cells. Innate defense protects the host, and at the same time, represents a major barrier to using adenoviruses as therapeutic interventions in humans. Innate response against adenoviruses involves intrinsic factors present at constant levels, and innate factors induced by the host cell upon viral challenge. These factors exert anti-viral effects by directly binding to viruses or viral components, or shield the virus, for example soluble factors, such as blood clotting components, the complement system, preexisting immunoglobulins or defensins. In addition, toll-like receptors and lectins in the plasma membrane and endosomes are intrinsic factors against adenoviruses. Important innate factors restricting adenovirus in the cytosol are tripartite motif-containing proteins (TRIM), nucleotide-binding oligomerization domain (NOD)-like inflammatory receptors and DNA sensors triggering interferon, such as DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 (DDX41) and cyclic guanosine monophosphate-adenosine monophosphate synthase (cGMP-AMP synthase, short cGAS). Adenovirus tunes the function of anti-viral autophagy, and counters innate defense by virtue of its early proteins E1A, E1B, E3 and E4 and two virus-associated noncoding RNAs VA-I and VA-II. We conclude by discussing strategies to engineer adenovirus vectors with attenuated innate responses and enhanced delivery features.
    Human gene therapy 02/2014; · 4.20 Impact Factor


Available from